08:55 AM EDT, 08/12/2024 (MT Newswires) -- Aethlon Medical ( AEMD ) said Monday that an Australian hospital has been granted full ethics approval by the Bellberry Human Research Ethics Committee for a clinical trial of its Hemopurifier in patients with solid tumors not responding to anti-PD-1 antibodies.

The approval granted to the Pindara Private Hospital in Queensland for a safety, feasibility and dose-finding trial is valid until Aug. 6, 2025, Aethlon Medical ( AEMD ) said.

"This is the second ethics committee approval we have received for our oncology trial in Australia after receiving approval from the ethics committee for Royal Adelaide Hospital in June," Aethlon's chief medical officer Steven LaRosa said.

Price: 0.2916, Change: -0.01, Percent Change: -2.80